Mutual of America Capital Management LLC Decreases Holdings in Solventum Corporation $SOLV

Mutual of America Capital Management LLC cut its holdings in shares of Solventum Corporation (NYSE:SOLV) by 1.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,903 shares of the company’s stock after selling 204 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Solventum were worth $1,206,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Rossby Financial LCC purchased a new stake in Solventum in the first quarter worth $25,000. Strengthening Families & Communities LLC increased its holdings in Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after acquiring an additional 260 shares during the last quarter. Barrett & Company Inc. increased its holdings in Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares during the last quarter. Hara Capital LLC purchased a new stake in Solventum in the 1st quarter worth about $38,000. Finally, Smartleaf Asset Management LLC increased its holdings in Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after acquiring an additional 352 shares during the last quarter.

Solventum Price Performance

Shares of NYSE:SOLV opened at $71.49 on Monday. The company’s fifty day moving average price is $72.62 and its 200-day moving average price is $72.21. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of 33.10, a PEG ratio of 2.91 and a beta of 0.50. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the company posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on SOLV. Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Argus raised Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a report on Tuesday, July 1st. UBS Group began coverage on Solventum in a report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price objective for the company. Wells Fargo & Company lifted their price objective on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a report on Monday, September 15th. Finally, Jefferies Financial Group began coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Solventum currently has an average rating of “Hold” and an average price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.